Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats
Joël Fort, Frédéric Oberti, Christophe Pilette, Nary Veal, Yves Gallois, Olivier Douay, Marie Christine Rousselet, Jean Rosenbaum, Paul Calès – 30 December 2003 – The aim of this study was to assess the effect of the early and chronic administration of octreotide in the prevention of hepatic fibrosis and portal hypertension (PHT). Two experimental models of liver fibrosis caused by bile duct ligation (BDL) or CCl4 were divided into 4 rat groups: sham, placebo, and octreotide (10 and 100 μg/kg twice daily, subcutaneously).